Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amur Minerals ( (GB:CRTX) ) has shared an announcement.
CRISM Therapeutics has published the results of an independent analysis of its shareholder register as at 31 December 2025, identifying five significant shareholders each holding at least 3% of its ordinary share capital, with CEO Andrew Webb the largest shareholder at 14.1%. The company also disclosed that, following its recent placing and retail offer completed in December 2025, former major shareholders Linista Group Inc. and Spreadex no longer hold disclosable stakes, signalling a reshaped investor base as CRISM advances its clinical development plans.
The most recent analyst rating on (GB:CRTX) stock is a Hold with a £9.50 price target. To see the full list of analyst forecasts on Amur Minerals stock, see the GB:CRTX Stock Forecast page.
Spark’s Take on GB:CRTX Stock
According to Spark, TipRanks’ AI Analyst, GB:CRTX is a Neutral.
The score is primarily held back by weak financial performance (minimal revenue, ongoing losses, and negative operating/free cash flow) despite improvement year over year. Technicals are also soft with the stock trading below key longer-term moving averages and a negative MACD. Valuation is difficult to support with a negative P/E and no dividend yield provided.
To see Spark’s full report on GB:CRTX stock, click here.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based clinical-stage drug delivery company focused on improving cancer treatment for solid tumours through localised and sustained delivery of chemotherapy drugs. Its lead product, ChemoSeed, is designed to be implanted directly into a tumour or surgical resection margin, enabling therapeutic concentrations of chemotherapy to reach deep-seated tumour tissue and, in indications such as glioblastoma, to bypass the blood-brain barrier during surgery. The company plans to start a registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in patients with surgically resectable glioblastoma in the first quarter of 2026.
Average Trading Volume: 120,350
Technical Sentiment Signal: Sell
Current Market Cap: £5.56M
See more data about CRTX stock on TipRanks’ Stock Analysis page.